CN103599477B - A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis - Google Patents
A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis Download PDFInfo
- Publication number
- CN103599477B CN103599477B CN201310567469.9A CN201310567469A CN103599477B CN 103599477 B CN103599477 B CN 103599477B CN 201310567469 A CN201310567469 A CN 201310567469A CN 103599477 B CN103599477 B CN 103599477B
- Authority
- CN
- China
- Prior art keywords
- parts
- plus
- ethanol
- accordance
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 9
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 9
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 9
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 9
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 9
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 9
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 9
- 244000001632 Acorus gramineus Species 0.000 claims abstract description 8
- 235000013073 Acorus gramineus Nutrition 0.000 claims abstract description 8
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 8
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 8
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 8
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 8
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 241000427159 Achyranthes Species 0.000 claims abstract description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 5
- 240000001519 Verbena officinalis Species 0.000 claims abstract description 5
- 235000018718 Verbena officinalis Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 239000006071 cream Substances 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- -1 filter Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000004383 Steviol glycoside Substances 0.000 claims 1
- 229930182488 steviol glycoside Natural products 0.000 claims 1
- 235000019411 steviol glycoside Nutrition 0.000 claims 1
- 150000008144 steviol glycosides Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000002307 prostate Anatomy 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 206010046555 Urinary retention Diseases 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004908 prostatic fluid Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis, it is characterized in that be made up of the raw material of following weight proportion：500 700 parts of dioscoreae septemlobae,rhizoma, 350 550 parts of Semen Cuscutae, 350 550 parts of Verbena officinalis, 200 300 parts of the fruit of Chinese magnoliavine, 350 550 parts of Herba Lycopi, 100 200 parts of indigo naturalis, 200 300 parts of spina gleditsiae, 350 550 parts of curcuma zedoary, 350 550 parts of calcined oyster shell, 200 300 parts of the root of three-nerved spicebush, 200 300 parts of grass-leaved sweetflag, 250 350 parts of the root of bidentate achyranthes.
Description
Technical field
The present invention relates to a kind of Chinese medicine, a kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis.
Background technology
Contemporary society's competition, rhythm of life is accelerated, and male's operating pressure is increasing.Overstretched, spirit
Fatigue, accumulates over a long period, and will trigger prostatitis, decline prostatic function, cause male sexual disorder.Therefore, before now
Row adenositis turns into the common disease and frequently-occurring disease of male, and prostatitis has complicated symptoms, course of disease delay, obstinate refractory, easy recurrence
The features such as, prostatitic patient can be usually seen in life and is repeatedly cured, the situation that can not all effect a radical cure.At present, before treatment
The method of row adenositis disease has a variety of, such as antibiotic therapy, treatment by Chinese herbs, injection treatment, physical treatment.Due to the spy of prostate
Different construction, prostate has unique anatomical position and physiological structure, although can quickly be removed due to prostate using antibiotic
Urinary tract symptom caused by inflammation, but be to cure the symptoms, not the disease, and most antibiotic can all produce antibiotics resistance, lesions of liver and kidney
Deng side effect, outcome is not known；Although medicine can be directly injected into prostate by injection treatment, it is easy to which spreading and reaching has
The antimicrobial concentration of effect, kills the bacterium of injection position and its surrounding tissue, drug moiety, which is absorbed into blood, can also cooperate with elimination
Urethra and the infection at other positions, still, because prostatic is deeper, direct injection not a duck soup, puncture can cause surrounding
Tissue damage simultaneously causes blood urine, makes prostatic hyperblastosis, prostatitis adenosclerosis；Physical treatment be by means of sound, light, electricity,
The various physical factors such as heat, water, using the thermodynamic activity produced by it, make deep tissue congested, improve blood circulation, reinforcement office
The nourishing of portion's tissue, accelerates the absorbing and eliminating of inflammatory products, but treatment trouble, and easily recur again very much；And Chinese traditional treatment is then reachable
To clearing heat and detoxicating, blood-activating analgetic, strengthen immunity of organisms, the overall effect treated both principal and secondary aspect of disease, but the Chinese patent drug of existing market sale,
Have due to compatibility not science, many does not all reach this effect.
Chronic prostatitis（Chronic Prostatitis, referred to as：CP）It is with irritation and the bladder genital area of urinating
Pain is the clinical syndrome that mainly shows, is the common disease and frequently-occurring disease [1] of adult male, and 50% male is in life
Once there was prostatitis medical history in certain period[2].One epidemiology survey at U.S. health statistics center shows, genito-urinary system
Chronic prostatitis accounts for 25% in system disease.
Because pathogenesis, the Pathological Physiology of chronic prostatitis change also not fully aware of, clinical progress is failed to understand again
Really, therefore, either doctor trained in Western medicine or the traditional Chinese medical science all using pain of alleviation, improve urination symptom and improve the quality of living be used as treatment mesh
Mark, the alleviation degree of symptom is to evaluate the Main Basiss for the treatment of of chronic prostatitis effect.Therefore a kind of determined curative effect, just is developed
There is positive social effect in the new drug for the treatment chronic prostatitis taken.By analyzing same veriety, find
Above with veriety effect with clearing heat and promoting diuresis, it is promoting blood circulation and removing blood stasis based on, taken second place with tonifying kidney and benefiting sperm, anti-inflammation kind is then detected in
Suppository of wild chrysanthemum flower.Medicament categories currently used for treatment chronic prostatitis are a lot, but have that curative effect is undesirable mostly, recurrence rate compared with
High defect, therefore the treatment of chronic prostatitis must formulate rational individualized treatment scheme under reliable clinical foundation,
And follow long-term, lasting, alternating, united principle of medication.
The content of the invention
The purpose of the present invention is intended to provide a kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis, Yi Zhongzhi
The Chinese medicine composition of humid-heat stagnation type chronic prostatitis is treated, it is characterized in that be made up of the raw material of following weight proportion：
500-700 parts of dioscoreae septemlobae,rhizoma, 350-550 parts of Semen Cuscutae, 350-550 parts of Verbena officinalis, 200--300 parts of the fruit of Chinese magnoliavine, Herba Lycopi
350-550 parts, 100-200 parts of indigo naturalis, 200--300 parts of spina gleditsiae, 350-550 parts of curcuma zedoary, 350-550 parts of calcined oyster shell, the root of three-nerved spicebush
200--300 parts, 200--300 parts of grass-leaved sweetflag, 250-350 parts of the root of bidentate achyranthes.
Further it is made up of the raw material of following weight proportion：
550-650 parts of dioscoreae septemlobae,rhizoma, 400-500 parts of Semen Cuscutae, 400-500 parts of Verbena officinalis, 200-300 parts of the fruit of Chinese magnoliavine, Herba Lycopi
400-500 parts, 130-180 parts of indigo naturalis, 200-300 parts of spina gleditsiae, 400-500 parts of curcuma zedoary, 400-500 parts of calcined oyster shell, the root of three-nerved spicebush
200-300 parts, 200-300 parts of grass-leaved sweetflag, 250-350 parts of the root of bidentate achyranthes.
Further it is made up of the raw material of following weight proportion：
600 portions of dioscoreae septemlobae,rhizoma, 450 portions of Semen Cuscutae, 450 portions of Verbena officinalis, 250 parts of the fruit of Chinese magnoliavine
450 parts of Herba Lycopi, 150 parts of indigo naturalis, 250 parts of spina gleditsiae, 450 parts of curcuma zedoary
450 parts of calcined oyster shell, 250 parts of the root of three-nerved spicebush, 250 parts of grass-leaved sweetflag, 300 parts of the root of bidentate achyranthes.
The present invention also provides a kind of method for preparing composition described in claim 1-3,
Dioscoreae septemlobae,rhizoma, the fruit of Chinese magnoliavine, indigo naturalis are taken, is decocted a drug wrapped, the taste of the root of three-nerved spicebush four, plus 55-65% ethanol extracts secondary, for the first time plus 11 times
Amount, immersion is extracted after 1 hour, second plus 10 times of amounts, and 1.5 hours every time, ethanol was recovered under reduced pressure to nothing in filtration, merging filtrate
Alcohol taste, clear cream is standby；Grass-leaved sweetflag and the taste of curcuma zedoary two, plus 6 times of amount water, soak 0.5 hour, are volatilized with extraction by steam distillation
Oil, filtration, the another device of the aqueous solution is preserved, and volatile oil is included with times his a ring paste, standby；The Six-elements such as the dregs of a decoction and Semen Cuscutae merge,
Extracting in water three times, adds 14 times of amounts for the first time, and immersion is extracted after 1 hour, and second and third time is respectively plus 12 times are measured, 1 hour every time, filter
Cross, filtrate merges with the above-mentioned aqueous solution, it is 1.05~1.10 to be concentrated into 60 DEG C of relative density, plus ethanol makes alcohol content reach 55-
65%, stir evenly, stand 24 hours, filtration, filtrate recycling ethanol merges with above-mentioned alcohol extracting clear cream to without alcohol taste, continues to be concentrated into phase
To the clear cream that 60 DEG C of density is 1.10~1.20；Clear cream is spray dried to dry extract.Add volatile oil clathrate compound, stevioside
Glycosides, dextrin: appropriate soluble starch, granulation, produce.
Ethanol described further is 60% ethanol.
Further volatile oil is with betadex by 1: 8 inclusion.
Further dextrin: soluble starch 2: 1.
Further extraction time is 3 hours.
Further 170 DEG C of spray drying EAT, hydrojet flow velocity 30rpm and atomizing pressure 0.2MPa.
Further granulation is using 95% ethanol as wetting agent.
（1）This prescription is using traditional Chinese medical theory as guidance, and prominent " invigorate the kidney and stop nocturnal emission to invigorate blood circulation with dampness removing and lay equal stress on " characteristic that opinion is controlled is led to
Cross invigorate the kidney and stop nocturnal emission, it is eliminating dampness and heat, promoting blood circulation and removing blood stasis, with up to the purpose for the treatment of humid-heat stagnation type chronic prostatitis.Theory has foundation,
Viewpoint has innovation.
（2）Volatile oil extracting, water extraction work is respectively adopted according to active ingredient in each medicine and its physicochemical property in extraction process
Skill and alcohol extraction process, and impurity and purification are carried out using alcohol precipitation mode to water extraction composition；Preparation process uses wet granulation, operation letter
It is single, good process repeatability.
（3）In quality research, the taste medicinal material of dioscoreae septemlobae,rhizoma etc. nine has been carried out thin layer differentiate research and will be wherein noiseless, exclusive
Property good gomi herbs dioscoreae septemlobae,rhizoma, spina gleditsiae, the root of bidentate achyranthes, the fruit of Chinese magnoliavine and curcuma zedoary are included in quality standard, in water extraction medicinal material Semen Cuscutae
Hyperoside and the alcohol extracting medicinal material fruit of Chinese magnoliavine in schizandrin carry out quantitative study, it is steady quality, controllable.
Embodiment
Further detailed description is done to the present invention with reference to the example of specific implementation.
【Prescription】
1st, composition
【Preparation method】
The taste of the above 12, takes dioscoreae septemlobae,rhizoma, the fruit of Chinese magnoliavine, indigo naturalis of decocting a drug wrapped, the taste of the root of three-nerved spicebush four, plus 60% ethanol to extract secondary, for the first time
Plus 11 times of amounts, extracted after soaking 1 hour, second plus 10 times of amounts 1.5 hours every time, are filtered, second is recovered under reduced pressure in merging filtrate
Alcohol is to without alcohol taste, and clear cream is standby；Grass-leaved sweetflag and the taste of curcuma zedoary two, plus 6 times of amount water, soak 0.5 hour, use extraction by steam distillation
Volatile oil 3 hours, filtration, the another device of the aqueous solution is preserved, and volatile oil is included with betadex by 1: 8, standby；The dregs of a decoction and Semen Cuscutae
Merge Deng Six-element, extracting in water three times, 14 times of amounts are added for the first time, immersion is extracted after 1 hour, second and third time is respectively plus 12 times are measured, often
Secondary 1 hour, filtration, filtrate merged with the above-mentioned aqueous solution, and it is 1.05~1.10 to be concentrated into 60 DEG C of relative density, plus ethanol makes containing alcohol
Amount is stirred evenly up to 60%, stands 24 hours, and filtration, filtrate recycling ethanol merges to without alcohol taste with above-mentioned alcohol extracting clear cream, continues to concentrate
To the clear cream that 60 DEG C of relative density is 1.10~1.20；Clear cream is spray dried to dry extract, adds volatile oil clathrate compound, stevia rebaudianum
Glucosides 10g, dextrin: soluble starch 2: 1 is appropriate, granulation are made 1000g, produced.
The retention of urine of effect example 1 is logical on the prostatitic influence of rat acute
Scheme:After male SD rat adaptability is fed, it is randomly divided into sham-operation, model, positive drug and the retention of urine and leads to particle
0.21g/kg, 0.62g/kg, 1.86g/kg group.Rat oral gavage gives the decoction that the retention of urine leads to particle formulation, sham-operation group and model
Group gavage gives physiological saline, and positive drug group gavage gives pervasive safe piece 0.72mg/kg.After 6th day administration 1h, in chloraldurate
（350mg/kg）Under anesthesia, median abdominal incision is removed up to abdominal cavity, exposure bladder dorsal part prostate injects 1% jiao in prostate notopodium
Dish glue normal saline solution 0.1ml is pitched, by prostata disease, layer-by-layer suture closes otch.Sham-operation group saline injection
0.1ml.Animal is put to death after 7th day gastric infusion 1h, massage of prostate liquid is taken, leukocyte count in expressed prostatic secretion and lecithin is determined
Small volume density.Rat acute prostatitis model modeling, after being administered 7 days, takes prostatic fluid, plate coating checking lecithin is close
Degree.Massage of prostate liquid 10ml, plus 190ml leucocyte dilutions are taken, takes and is counted under 10l microscopes after mixing.As a result it is visible, with
Sham-operation group is compared, and leukocyte count significantly rises in model group rats prostatic fluid, and lecithin density is remarkably decreased, the retention of urine
Logical 1.86g/kg can obviously reduce the lecithin density in the leukocyte count in prostatic fluid, rise prostatic fluid（Table 1）.
Logical prostatitic on the rat acute influence of the retention of urine of table 1. (±s)
**P<0.01vs sham-operation groups；#P<0.05, ##P<0.01vs model groups
The logical influence to rat chronic prostatitis leukocyte count and lecithin density of the retention of urine of effect example 2
Scheme：Male Wistar rat, body weight 180-210g, after adaptability is fed, chloral hydrate anesthesia（350mg/kg）,
Aseptic condition median incision of lower abdomen, abdominal cavity of going directly proposes bladder and both sides seminal vesicle, and exposure invests the prostate back of the body on the inside of seminal vesicle
Leaf, the common 0.2ml of 25% XIAOZHILING ZHUSHEYE, sham-operation group injection 0.2ml physiological saline are injected separately into per side.By prostata disease,
Layer-by-layer suture closes otch.After modeling 7d, in addition to sham-operation group, modeling rat is randomly divided into 5 groups, respectively model group, pervasive
Safe piece 0.72mg/kg, the retention of urine lead to 0.21g/kg, 0.62g/kg, 1.86g/kg group.Each daily gastric infusion of administration group, model group
And sham-operation group gives isometric physiological saline.Animal is put to death after 28d gastric infusions 1h, massage of prostate liquid and prostatitis is taken
Glandular tissue, determines leukocyte count in expressed prostatic secretion and lecithin density, prepares tissue homogenate to be measured.Prostata tissue Fu Er
Malin fixes, and HE dyeing carries out histopathologic examination.After rat chronic prostatitis modeling, it is administered 28 days.After last dose
Detect prostate leukocyte count and lecithin density.As a result it is visible compared with sham-operation group, model group rats prostatic fluid
Interior leukocyte count significantly rises, and lecithin density is remarkably decreased.The retention of urine leads to each dosage and can obviously reduce in prostatic fluid
Leukocyte count, raises lecithin density（Table 2）.
The retention of urine of table 2 it is logical to rat chronic prostatitis lecithin density and leukocyte count influence (±s)
**P<0.01vs sham-operation groups；#P<0.05, ##P<0.01vs model groups
Although the present invention obtains clear explanation by above example, but without departing substantially from spirit of the invention and in fact
In the case of matter, person of ordinary skill in the field works as can make various corresponding variations and modifications, but this according to the present invention
A little corresponding variations and modifications should all belong to the scope of the claims of the present invention.
Claims (8)
1. a kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis, it is made up of the raw material of following weight proportion
's：
600 portions of dioscoreae septemlobae,rhizoma, 450 portions of Semen Cuscutae, 450 portions of Verbena officinalis, 250 parts of the fruit of Chinese magnoliavine
450 parts of Herba Lycopi, 150 parts of indigo naturalis, 250 parts of spina gleditsiae, 450 parts of curcuma zedoary
450 parts of calcined oyster shell, 250 parts of the root of three-nerved spicebush, 250 parts of grass-leaved sweetflag, 300 parts of the root of bidentate achyranthes.
2. a kind of method for preparing Chinese medicine composition as claimed in claim 1, it is characterised in that：
Take dioscoreae septemlobae,rhizoma, the fruit of Chinese magnoliavine, indigo naturalis and the taste of the root of three-nerved spicebush four, plus 55-65% ethanol to extract secondary, 11 times of amounts, immersion 1 are added for the first time
Extracted after hour, second plus 10 times of amounts, 1.5 hours every time, ethanol is recovered under reduced pressure to without alcohol taste, clear cream in filtration, merging filtrate
It is standby；Grass-leaved sweetflag and the taste of curcuma zedoary two, plus 6 times of amount water, soak 0.5 hour, use extraction by steam distillation volatile oil, filter, water
The another device of solution is preserved, and volatile oil is included with betadex, standby；The dregs of a decoction merge with remaining Six-element, extracting in water three times,
For the first time plus 14 times amount, immersion 1 hour after extract, second and third time respectively plus 12 times amount, 1 hour every time, filtration, filtrate with it is above-mentioned
The aqueous solution merges, and relative density when being concentrated into 60 DEG C is 1.05~1.10, plus ethanol makes alcohol content reach 55-65%, stirs evenly, quiet
Put 24 hours, filter, filtrate recycling ethanol merges with above-mentioned alcohol extracting clear cream to without alcohol taste, it is relative when continuing to be concentrated into 60 DEG C
Density is 1.10~1.20 clear cream；Clear cream is spray dried to dry extract, adds volatile oil clathrate compound, steviol glycoside, dextrin
Appropriate with soluble starch, granulation is produced.
3. in accordance with the method for claim 2, it is characterised in that the ethanol is 60%.
4. in accordance with the method for claim 2, it is characterised in that the volatile oil is included with betadex 1: 8.
5. in accordance with the method for claim 2, it is characterised in that the dextrin is 2: 1 with soluble starch.
6. in accordance with the method for claim 2, it is characterised in that the extraction time during extraction volatile oil is 3 hours.
7. in accordance with the method for claim 2, it is characterised in that the EAT during spray drying is 170 DEG C, hydrojet
Flow velocity is that 30rpm, atomizing pressure are 0.2MPa.
8. in accordance with the method for claim 2, it is characterised in that using 95% ethanol as wetting agent in the granulating process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310567469.9A CN103599477B (en) | 2013-11-14 | 2013-11-14 | A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310567469.9A CN103599477B (en) | 2013-11-14 | 2013-11-14 | A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599477A CN103599477A (en) | 2014-02-26 |
| CN103599477B true CN103599477B (en) | 2017-08-08 |
Family
ID=50117783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310567469.9A Active CN103599477B (en) | 2013-11-14 | 2013-11-14 | A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599477B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027700A (en) * | 2014-06-24 | 2014-09-10 | 广西中医药大学 | Traditional Chinese medicine composition for treating chronic prostatitis and preparation method thereof |
| CN118692588B (en) * | 2024-08-22 | 2024-10-25 | 沈阳神龙药业有限公司 | A method and system for automatically detecting the quality of traditional Chinese medicine for treating prostate diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698126A (en) * | 2012-04-12 | 2012-10-03 | 江苏建康职业学院 | Traditional Chinese medicine compound having effect of treating prostatitis and preparation method thereof |
-
2013
- 2013-11-14 CN CN201310567469.9A patent/CN103599477B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698126A (en) * | 2012-04-12 | 2012-10-03 | 江苏建康职业学院 | Traditional Chinese medicine compound having effect of treating prostatitis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 萆菟汤治疗慢性前列腺炎180例;陈应前等;《辽宁中医要大学学报》;20081231;第10卷;114-115 * |
| 金保方教授运用萆菟汤治疗泌尿生殖系疾病验案5则;孙大林等;《新中医》;20110630;第43卷(第6期);172-174 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599477A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102018810B (en) | Preparation method of compound Houttuynia cordata mixture | |
| CN102988899B (en) | Traditional Chinese medicine composition used for treating obstruction of breast milk secretion | |
| CN101780227A (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN103845418A (en) | Chinese medicinal composition for treating fundus hemorrhage and application thereof | |
| CN103599477B (en) | A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN103099885A (en) | Soft capsules having acne removing function and preparation method thereof | |
| CN103860977B (en) | A kind of pharmaceutical composition for the treatment of dermatitis | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN105362533A (en) | Nursing lacrimal passage flushing fluid for infantile dacryocystitis and preparation method of flushing fluid | |
| CN104689079A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof | |
| CN104491324A (en) | Aerosol for postoperative patient to promote blood circulation and remove obstruction in channels | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103860976B (en) | A kind of pharmaceutical composition for the treatment of infant's dermatitis | |
| CN105663838A (en) | Traditional Chinese medicine for treating choledocholithiasis by combining epidural anesthesia and preparation method | |
| CN1927273A (en) | Bath agent for influenza defervesce and preparing method thereof | |
| CN105267688A (en) | Medicine for treating edema disease of pigs and preparing method thereof | |
| CN104474255A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition | |
| CN105770515A (en) | Traditional Chinese medicinal composition for treating prostatitis and preparation method of traditional Chinese medicinal composition | |
| CN105267632A (en) | Traditional Chinese medicine composition composition treating diabetic macular edema | |
| CN104225506A (en) | Medicinal preparation for treating thrombocytopenia after chemotherapy | |
| CN117503880A (en) | Traditional Chinese medicine composition for treating chronic eczema, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 225441, Jiangsu, Taixing province Daqing West Road, pagoda Bay, Sichuan Pharmaceutical Group, Limited by Share Ltd Applicant after: Jumpcan Pharmaceutical Group Co., Ltd. Address before: 225441, Jiangsu, Taixing province Daqing West Road, pagoda Bay, Sichuan Pharmaceutical Group, Limited by Share Ltd Applicant before: Jumpcan Pharmaceutical Group Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |